Drugmakers and pharmacy disagree over who gets to make the drugs

The US Food and Drug Administration (FDA) has issued a warning to a California pharmacy over allegations that it made a copy of Novo Nordisk’s obesity drug ‘Ozempic’. This comes after Novo Nordisk asked the FDA to add semaglutide, the key ingredient in Ozempic, to its list of drugs deemed too difficult to compound safely. Novo Nordisk said it has filed several lawsuits against compounders.